{
    "organizations": [],
    "uuid": "e581faa73c0a738da9f6da715bd7c317123d9285",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-nerlynx-include/brief-puma-biotechnology-nerlynx-included-as-recommended-treatment-option-in-nccn-clinical-practice-guidelines-idUSFWN1RF07K",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2 (Reuters) - Puma Biotechnology Inc:\n* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS\n* NCCN GUIDELINES INCLUDE NERLYNX IN COMBINATION WITH CAPECITABINE/ PACLITAXEL AS TREATMENT OPTIONS WITH BREAST CANCER BRAIN METASTASES​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-04-02T21:09:00.000+03:00",
    "crawled": "2018-04-03T16:12:47.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "included",
        "recommended",
        "treatment",
        "option",
        "nccn",
        "clinical",
        "practice",
        "guideline",
        "oncology",
        "central",
        "nervous",
        "system",
        "cancer",
        "nccn",
        "guideline",
        "include",
        "nerlynx",
        "combination",
        "paclitaxel",
        "treatment",
        "option",
        "breast",
        "cancer",
        "brain",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}